Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.69 |
| ▸ | LMNA | P02545 | 5/20 | 0.69 |
| ▸ | HTT | P42858 | 4/20 | 0.69 |
| ▸ | HPGD | P15428 | 4/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.69 |
| ▸ | PGR | P06401 | 2/20 | 0.69 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.69 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.69 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.69 |
| ▸ | PDE4A | P27815 | 1/20 | 0.69 |
| ▸ | HRH1 | P35367 | 1/20 | 0.69 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.69 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.56 |
| ▸ | RAB9A | P51151 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 3/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4436683 | 0.89 | CES2 (0.57) | ALDH1A1LMNAHTTHPGDMAPK1 | |
| SCHEMBL6203813 | 0.87 | ALDH1A1 (0.65) | ALDH1A1LMNAHTTHPGDMAPK1 | |
| SCHEMBL11575545 | 0.86 | HTT (0.59) | ALDH1A1LMNAHTTHPGDMAPK1 | |
| SCHEMBL2945284 | 0.82 | CYP1A2 (0.71) | ALDH1A1LMNAHTTHPGDMAPK1 | |
| SCHEMBL3224251 | 0.82 | NPC1 (0.81) | ALDH1A1LMNAHTTHPGDMAPK1 | |
| Oxybenzone SCHEMBL15551 | 0.82 | HPGD (1.00) | ALDH1A1LMNAHTTHPGDMAPK1 | |
| SCHEMBL699230 | 0.82 | ALDH1A1 (0.71) | ALDH1A1LMNAHTTHPGDMAPK1 | |
| Oxybenzone SCHEMBL6674080 | 0.82 | HPGD (1.00) | ALDH1A1LMNAHTTHPGDMAPK1 | |
| SCHEMBL3480945 | 0.82 | ALDH1A1 (0.71) | ALDH1A1LMNAHTTHPGDMAPK1 | |
| Oxybenzone SCHEMBL5161586 | 0.82 | HPGD (1.00) | ALDH1A1LMNAHTTHPGDMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6943189-B2 | Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG CO-A reductase inhibitors | G.D. SEARLE & CO. (US) | 2005-09-13 | — | — | US | disclosed |
| EP-0888333-B1 | NOVEL BENZOTHIEPINES HAVING ACTIVITY AS INHIBITORS OF ILEAL BILE ACID TRANSPORT AND TAUROCHOLATE UPTAKE | SEARLE LLC (US) | 2005-08-31 | — | — | EP | disclosed |
| EP-1448546-A4 | NOVEL MONO- AND DI-FLUORINATED BENZOTHIEPINE COMPOUNDS AS INHIBITORS OF APICAL SODIUM CO-DEPENDENT BILE ACID TRANSPORT (ASBT) AND TAUROCHOLATE UPTAKE | SEARLE LLC (US) | 2005-02-02 | — | — | EP | disclosed |
| US-20040204478-A1 | Novel benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake | G.D. SEARLE & COMPANY | 2004-10-14 | — | — | US | disclosed |
| US-20040176438-A1 | Novel mono- and di-fluorinated beozothiepine copmunds as inhibitors of apical sodium co-dependent bile acid transport (ASBT) and taurocholate uptake | G.D. SEARLE, LLC | 2004-09-09 | — | — | US | disclosed |
| US-6784201-B2 | FOR PROPHYLAXIS AND TREATMENT OF HYPERLIPIDEMIC CONDITIONS SUCH AS THOSE ASSOCIATED WITH ATHEROSCLEROSIS OR HYPERCHOLESTEROLEMIA | G.D. SEARLE & COMPANY | 2004-08-31 | — | — | US | disclosed |
| EP-1448546-A1 | NOVEL MONO- AND DI-FLUORINATED BENZOTHIEPINE COMPOUNDS AS INHIBITORS OF APICAL SODIUM CO-DEPENDENT BILE ACID TRANSPORT (ASBT) AND TAUROCHOLATE UPTAKE | G.D. Searle LLC (US) | 2004-08-25 | — | — | EP | disclosed |
| US-20040157915-A1 | Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors | G.D. SEARLE & CO. (US) | 2004-08-12 | — | — | US | disclosed |
| EP-1440972-A1 | Novel benzothiepines having pharmaceutical activity. | G.D. Searle & Co. (US) | 2004-07-28 | — | — | EP | disclosed |
| US-6740663-B2 | ANTIHYPERLIPIDEMIC AGENTS | G.D. SEARLE, LLC | 2004-05-25 | — | — | US | disclosed |
| EP-0888333-A1 | NOVEL BENZOTHIEPINES HAVING ACTIVITY AS INHIBITORS OF ILEAL BILE ACID TRANSPORT AND TAUROCHOLATE UPTAKE | G.D. Searle & Co. (US) | 1999-01-07 | — | — | EP | disclosed |
| US-5817652-A | ATHEROSCLEROSIS | GLAXO WELLCOME INC. (US) | 1998-10-06 | — | — | US | disclosed |
| WO-1998040375-A2 | COMBINATION OF ILEAL BILE ACID TRANSPORT INHIBITING BENZOTHIEPINES AND HMG Co-A REDUCTASE INHIBITORS | G.D. SEARLE & CO. (US) | 1998-09-17 | — | — | WO | disclosed |
| US-5723458-A | 1,4-BENZOTHIAZEPINES | GLAXO WELLCOME INC. (US) | 1998-03-03 | — | — | US | disclosed |
| WO-1997033882-A9 | NOVEL BENZOTHIEPINES HAVING ACTIVITY AS INHIBITORS OF ILEAL BILE ACID TRANSPORT AND TAUROCHOLATE UPTAKE | — | 1998-02-26 | — | — | WO | disclosed |
| WO-1997033882-A1 | NOVEL BENZOTHIEPINES HAVING ACTIVITY AS INHIBITORS OF ILEAL BILE ACID TRANSPORT AND TAUROCHOLATE UPTAKE | G.D. SEARLE AND CO. (US) | 1997-09-18 | — | — | WO | disclosed |
| EP-0781278-A1 | NOVEL BENZOTHIEPINES HAVING ACTIVITY AS INHIBITORS OF ILEAL BILE ACID TRANSPORT AND TAUROCHOLATE UPTAKE | MONSANTO COMPANY (US) | 1997-07-02 | — | — | EP | disclosed |
| EP-0775126-A1 | HYPOLIPIDEMIC 1,4-BENZOTHIAZEPINE-1,1-DIOXIDES | THE WELLCOME FOUNDATION LIMITED (GB) | 1997-05-28 | — | — | EP | disclosed |
| WO-1996008484-A1 | NOVEL BENZOTHIEPINES HAVING ACTIVITY AS INHIBITORS OF ILEAL BILE ACID TRANSPORT AND TAUROCHOLATE UPTAKE | MONSANTO COMPANY (US) | 1996-03-21 | — | — | WO | disclosed |
| WO-1996005188-A1 | HYPOLIPIDEMIC 1,4-BENZOTHIAZEPINE-1,1-DIOXIDES | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204478-A1 | Novel benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake | SLC10A2, SLC10A1, ABCB11 | ALDH1A1 4110/4885LMNA 3300/4885HTT 1111/4885 |
| US-20040157915-A1 | Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors | SLC10A2, SLC10A1, HMGCR | ALDH1A1 2114/4885LMNA 1897/4885HTT 1988/4885 |
| US-20040176438-A1 | Novel mono- and di-fluorinated beozothiepine copmunds as inhibitors of apical sodium co-dependent bile acid transport (ASBT) and taurocholate uptake | SLC10A1, SLC10A2, ABCB11 | ALDH1A1 3185/4885LMNA 4622/4885HTT 1099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.